SCHEMBL23934283

SCHEMBL23934283

N#Cc1ccc(C(=O)Nc2ccc(NC(=O)c3ccc(C#N)cc3)c3c2C(=O)NC3=O)cc1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.49
RXFP1 Q9HBX9 2/20 0.49
KMT2A Q03164 4/20 0.47
MEN1 O00255 3/20 0.47
MMP1 P03956 1/20 0.47
MLYCD O95822 1/20 0.47
NPC1 O15118 3/20 0.46
RAB9A P51151 3/20 0.46
DEGS1 O15121 1/20 0.46
CYP11B1 P15538 1/20 0.46
CYP11B2 P19099 1/20 0.46
CASP3 P42574 2/20 0.45
ESR1 P03372 1/20 0.45
ALDH1A1 P00352 2/20 0.44
KDM4E B2RXH2 1/20 0.44
HTT P42858 1/20 0.44
PKM P14618 1/20 0.44
GPR35 Q9HC97 1/20 0.43
NAMPT P43490 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23934265 0.79 POLB (0.50) POLBRXFP1KMT2AMEN1MMP1
SCHEMBL8417469 0.77 MMP1 (0.65) POLBRXFP1KMT2AMEN1MMP1
SCHEMBL23934274 0.75 KMT2A (0.46) RXFP1KMT2AMEN1MLYCDNPC1
SCHEMBL12635983 0.74 KMT2A (0.69) POLBRXFP1KMT2AMEN1NPC1
SCHEMBL18170781 0.74 KDR (0.58) KMT2AMEN1MMP1NPC1RAB9A
SCHEMBL6263516 0.73 MLYCD (0.76) POLBKMT2AMEN1MLYCDNPC1
SCHEMBL9337665 0.73 MLYCD (0.76) POLBKMT2AMEN1MLYCDNPC1
SCHEMBL6359401 0.73 ALB (0.63) POLBRXFP1KMT2AMEN1NPC1
SCHEMBL12501958 0.72 RAB9A (0.56) POLBRXFP1KMT2AMEN1NPC1
SCHEMBL943285 0.72 KDM5A (0.53) POLBRXFP1KMT2AMEN1MMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912660-B2 S6K1 protein kinase inhibitors as cancer therapeutics XAVIER UNIVERSITY OF LOUISIANA (US) 2024-02-27 US disclosed
US-20210323919-A1 S6K1 PROTEIN KINASE INHIBITORS AS CANCER THERAPEUTICS XAVIER UNIVERSITY OF LOUISIANA 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210323919-A1 S6K1 PROTEIN KINASE INHIBITORS AS CANCER THERAPEUTICS RPS6KA6, RPS6KA1, RPS6KA3 POLB 3272/4885RXFP1 2817/4885KMT2A 2003/4885
US-11912660-B2 S6K1 protein kinase inhibitors as cancer therapeutics RPS6KA6, RPS6KA1, RPS6KA3 POLB 3272/4885RXFP1 2817/4885KMT2A 2003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.